Antifungal Treatment of Small Animal Veterinary Patients

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 6, 2010, Pages 1171-1188

  Foy, Daniel S ^a   Trepanier, Lauren A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Amphotericin B; Antifungal; Azole; Systemic mycoses

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; CASPOFUNGIN; CHOLESTEROL SULFATE; CLOTRIMAZOLE; CYCLOSPORIN; DEOXYCHOLATE SODIUM; DEXAMETHASONE; DIGOXIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; ENILCONAZOLE; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LIPOSOME; METOCLOPRAMIDE; MIDAZOLAM; NEW DRUG; POSACONAZOLE; PROPYLENE GLYCOL; PROTON PUMP INHIBITOR; SODIUM; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

ANAPHYLAXIS; ANTIFUNGAL THERAPY; ASPERGILLOSIS; AUDITORY HALLUCINATION; BLASTOMYCOSIS; BLURRED VISION; CANDIDIASIS; CELL METABOLISM; COCCIDIOIDOMYCOSIS; COLOR VISION; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG THERAPY; DRUG TISSUE LEVEL; FUNGAL CELL; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPLASMOSIS; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER TOXICITY; MALASSEZIA DERMATITIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OTITIS; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTEMIC MYCOSIS; VETERINARY MEDICINE; VISUAL HALLUCINATION;

ANIMALS; ANTIFUNGAL AGENTS; CAT DISEASES; CATS; DOG DISEASES; DOGS; MYCOSES; VETERINARY DRUGS;

ANIMALIA;

EID: 77957367129     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.07.006     Document Type: Review

References (144)

1. Saliba F., Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008, 46(2):97-112.
2. Thompson G.R., Cadena J., Patterson T.F. Overview of antifungal agents. Clin Chest Med 2009, 30(2):203-215. v.
3. Spanakis E.K., Aperis G., Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006, 43(8):1060-1068.
4. Rachwalski E.J., Wieczorkiewicz J.T., Scheetz M.H. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008, 42(10):1429-1438.
5. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996, 9(4):512-531.
6. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties?. Biochim Biophys Acta 1986, 864(3-4):257-304.
7. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990, 12(2):308-329.
8. Khoo S.H., Bond J., Denning D.W. Administering amphotericin B-a practical approach. J Antimicrob Chemother 1994, 33(2):203-213.
9. Costa S., Nucci M. Can we decrease amphotericin nephrotoxicity?. Curr Opin Crit Care 2001, 7(6):379-383.
10. Gerkens J.F., Branch R.A. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980, 214(2):306-311.
11. Sawaya B.P., Weihprecht H., Campbell W.R., et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991, 87(6):2097-2107.
12. Ohnishi A., Ohnishi T., Stevenhead W., et al. Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrobial Agents Chemother 1989, 33(8):1222-1227.
13. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26(6):1383-1396.
14. Herbrecht R., Natarajan-Ame S., Nivoix Y., et al. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003, 4(8):1277-1287.
15. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996, 22(Suppl 2):S133-S144.
16. Tiphine M., Letscher-Bru V., Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999, 1(4):273-283.
17. Hay R.J. Liposomal amphotericin B, AmBisome. J Infect 1994, 28(Suppl 1):35-43.
18. de Marie S., Janknegt R., Bakker-Woudenberg I.A. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994, 33(5):907-916.
19. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994, 14(Suppl 5):S3-S7.
20. Bekersky I., Boswell G.W., Hiles R., et al. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 1999, 16(11):1694-1701.
21. Kim H., Loebenberg D., Marco A., et al. Comparative pharmacokinetics of SCH 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrobial Agents Chemother 1984, 26(4):446-449.
22. Janoff A.S., Boni L.T., Popescu M.C., et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A 1988, 85(16):6122-6126.
23. Olsen S.J., Swerdel M.R., Blue B., et al. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991, 43(12):831-835.
24. Adedoyin A., Swenson C.E., Bolcsak L.E., et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrobial Agents Chemother 2000, 44(10):2900-2902.
25. Swenson C.E., Perkins W.R., Roberts P., et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?. Antimicrobial Agents Chemother 1998, 42(4):767-771.
26. Janoff A.S., Perkins W.R., Saletan S.L., et al. Amphotericin B lipid complex (ABLC™):a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993, 3(3):451-471.
27. Krawiec D.R., McKiernan B.C., Twardock A.R., et al. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs. J Am Vet Med Assoc 1996, 209(12):2073-2075.
28. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996, 10(Suppl 2):s93-s96.
29. Herbrecht R., Letscher V., Andres E., et al. Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 1999, 45(Suppl 1):67-76.
30. Fielding R.M., Singer A.W., Wang L.H., et al. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents Chemother 1992, 36(2):299-307.
31. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998, 27(3):603-618.
32. Barrett J.P., Vardulaki K.A., Conlon C., et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003, 25(5):1295-1320.
33. Llanos A., Cieza J., Bernardo J., et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991, 40(2):302-308.
34. Turcu R., Patterson M.J., Omar S. Influence of sodium intake on amphotericin B-induced nephrotoxicity among extremely premature infants. Pediatr Nephrol 2009, 24(3):497-505.
35. Anderson C.M. Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care?. West J Med 1995, 162(4):313-317.
36. Del Bono V., Mikulska M., Viscoli C. Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol 2008, 15(6):586-593.
37. Knoper S.R., Galgiani J.N. Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis. Infect Dis Clin North Am 1988, 2(4):861-875.
38. Kotwani R.N., Gokhale P.C., Bodhe P.V., et al. Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis. J Assoc Physicians India 2001, 49:1086-1090.
39. Saag M.S., Dismukes W.E. Treatment of histoplasmosis and blastomycosis. Chest 1988, 93(4):848-851.
40. Taylor R.L., Williams D.M., Craven P.C., et al. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis 1982, 125(5):610-611.
41. Arceneaux K.A., Taboada J., Hosgood G. Blastomycosis in dogs: 115 cases (1980-1995). J Am Vet Med Assoc 1998, 213(5):658-664.
42. Graupmann-Kuzma A., Valentine B.A., Shubitz L.F., et al. Coccidioidomycosis in dogs and cats: a review. J Am Anim Hosp Assoc 2008, 44(5):226-235.
43. Mitchell M., Stark D.R. Disseminated canine histoplasmosis: a clinical survey of 24 cases in Texas. Can Vet J 1980, 21(3):95-100.
44. O'Brien C.R., Krockenberger M.B., Martin P., et al. Long-term outcome of therapy for 59 cats and 11 dogs with cryptococcosis. Aust Vet J 2006, 84(11):384-392.
45. Schultz R.M., Johnson E.G., Wisner E.R., et al. Clinicopathologic and diagnostic imaging characteristics of systemic aspergillosis in 30 dogs. J Vet Intern Med 2008, 22(4):851-859.
46. Kauffman C.A. Role of azoles in antifungal therapy. Clin Infect Dis 1996, 22(Suppl 2):S148-S153.
47. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999, 12(1):40-79.
48. Groll A.H., De Lucca A.J., Walsh T.J. Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol 1998, 6(3):117-124.
49. Zonios D.I., Bennett J.E. Update on azole antifungals. Semin Respir Crit Care Med 2008, 29(2):198-210.
50. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330(4):263-272.
51. Pea F., Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001, 40(11):833-868.
52. Zhou R., Moench P., Heran C., et al. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm Res 2005, 22(2):188-192.
53. Treatment of blastomycosis and histoplasmosis with ketoconazole Results of a prospective randomized clinical trial. National institute of allergy and infectious diseases mycoses study group. Ann Intern Med 1985, 103(6 (Pt 1)):861-872.
54. Clinkenbeard K.D., Cowell R.L., Tyler R.D. Disseminated histoplasmosis in dogs: 12 cases (1981-1986). J Am Vet Med Assoc 1988, 193(11):1443-1447.
55. Hodges R.D., Legendre A.M., Adams L.G., et al. Itraconazole for the treatment of histoplasmosis in cats. J Vet Intern Med 1994, 8(6):409-413.
56. Legendre A.M., Rohrbach B.W., Toal R.L., et al. Treatment of blastomycosis with itraconazole in 112 dogs. J Vet Intern Med 1996, 10(6):365-371.
57. Bromel C., Sykes J.E. Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats. Clin Tech Small Anim Pract 2005, 20(4):233-239.
58. Bromel C., Sykes J.E. Histoplasmosis in dogs and cats. Clin Tech Small Anim Pract 2005, 20(4):227-232.
59. Negre A., Bensignor E., Guillot J. Evidence-based veterinary dermatology: a systematic review of interventions for malassezia dermatitis in dogs. Vet Dermatol 2009, 20(1):1-12.
60. Mayer U.K., Glos K., Schmid M., et al. Adverse effects of ketoconazole in dogs-a retrospective study. Vet Dermatol 2008, 19(4):199-208.
61. Medleau L., Chalmers S.A. Ketoconazole for treatment of dermatophytosis in cats. J Am Vet Med Assoc 1992, 200(1):77-78.
62. Brusko C.S., Marten J.T. Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. DICP 1991, 25(12):1321-1325.
63. Rodriguez R.J., Acosta D. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995, 96(2):83-92.
64. Rodriguez R.J., Acosta D. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997, 117(2-3):123-131.
65. Rodriguez R.J., Buckholz C.J. Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica 2003, 33(4):429-441.
66. Hugnet C., Lespine A., Alvinerie M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J Pharm Pharm Sci 2007, 10(3):311-318.
67. Kuroha M., Azumano A., Kuze Y., et al. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metab Dispos 2002, 30(1):63-68.
68. Dahlinger J., Gregory C., Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 1998, 27(1):64-68.
69. McAnulty J.F., Lensmeyer G.L. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet Surg 1999, 28(6):448-455.
70. De Coster R., Beerens D., Dom J., et al. Endocrinological effects of single daily ketoconazole administration in male beagle dogs. Acta Endocrinol (Copenh) 1984, 107(2):275-281.
71. Lien Y.H., Huang H.P. Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994-2007). J Am Vet Med Assoc 2008, 233(12):1896-1901.
72. Brammer K.W., Farrow P.R., Faulkner J.K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990, 12(Suppl 3):S318-S326.
73. Latimer F.G., Colitz C.M., Campbell N.B., et al. Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses. Am J Vet Res 2001, 62(10):1606-1611.
74. Vaden S.L., Heit M.C., Hawkins E.C., et al. Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J Vet Pharmacol Ther 1997, 20(3):181-186.
75. Diaz M., Negroni R., Montero-Gei F., et al. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis 1992, 14(Suppl 1):S68-S76.
76. Pappas P.G., Bradsher R.W., Chapman S.W., et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1995, 20(2):267-271.
77. Saag M.S., Powderly W.G., Cloud G.A., et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID mycoses study group and the AIDS clinical trials group. N Engl J Med 1992, 326(2):83-89.
78. Lim S.G., Sawyerr A.M., Hudson M., et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993, 7(3):317-321.
79. Humphrey M.J., Jevons S., Tarbit M.H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents Chemother 1985, 28(5):648-653.
80. Jezequel S.G. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol 1994, 46(3):196-199.
81. Malik R., Wigney D.I., Muir D.B., et al. Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. J Med Vet Mycol 1992, 30(2):133-144.
82. Pursley T.J., Blomquist I.K., Abraham J., et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996, 22(2):336-340.
83. Smith J., Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008, 30(2):167-172.
84. Kanda Y., Kami M., Matsuyama T., et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998, 16(1):33-37.
85. Jacobs G.J., Medleau L., Calvert C., et al. Cryptococcal infection in cats: factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats. J Vet Intern Med 1997, 11(1):1-4.
86. Pasqualotto A.C., Denning D.W. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents 2007, 30(1):93-94.
87. Denning D.W., Tucker R.M., Hanson L.H., et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989, 149(10):2301-2308.
88. Glasmacher A., Hahn C., Leutner C., et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999, 42(7-8):443-451.
89. Warnock D.W., Turner A., Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988, 21(1):93-100.
90. Kramer M.R., Marshall S.E., Denning D.W., et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990, 113(4):327-329.
91. Sachs M.K., Blanchard L.M., Green P.J. Interaction of itraconazole and digoxin. Clin Infect Dis 1993, 16(3):400-403.
92. Olkkola K.T., Backman J.T., Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994, 55(5):481-485.
93. Lebrun-Vignes B., Archer V.C., Diquet B., et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001, 51(5):443-450.
94. Haria M., Bryson H.M., Goa K.L. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996, 51(4):585-620.
95. Barone J.A., Moskovitz B.L., Guarnieri J., et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrobial Agents Chemother 1998, 42(7):1862-1865.
96. Boothe D.M., Herring I., Calvin J., et al. Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Am J Vet Res 1997, 58(8):872-877.
97. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415.
98. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36(5):630-637.
99. Li R.K., Ciblak M.A., Nordoff N., et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrobial Agents Chemother 2000, 44(6):1734-1736.
100. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346(4):225-234.
101. Scherpbier H.J., Hilhorst M.I., Kuijpers T.W. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 2003, 37(6):828-830.
102. Tsiodras S., Zafiropoulou R., Kanta E., et al. Painful peripheral neuropathy associated with voriconazole use. Arch Neurol 2005, 62(1):144-146.
103. Vandecasteele S.J., Van Wijngaerden E., Peetermans W.E. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Infect Dis 2004, 23(8):656-657.
104. Cronin S., Chandrasekar P.H. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010, 65(3):410-416.
105. Roffey S.J., Cole S., Comby P., et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003, 31(6):731-741.
106. Okabayashi K., Imaji M., Osumi T., et al. Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses. Nippon Ishinkin Gakkai Zasshi 2009, 50(2):91-94.
107. Diekema D.J., Messer S.A., Hollis R.J., et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003, 41(8):3623-3626.
108. Pfaller M.A., Messer S.A., Boyken L., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005, 43(5):2163-2167.
109. Catanzaro A., Cloud G.A., Stevens D.A., et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007, 45(5):562-568.
110. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998, 36(10):2950-2956.
111. Courtney R., Radwanski E., Lim J., et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrobial Agents Chemother 2004, 48(3):804-808.
112. Courtney R., Wexler D., Radwanski E., et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004, 57(2):218-222.
113. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4):348-359.
114. Wexler D., Courtney R., Richards W., et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004, 21(5):645-653.
115. Sansone-Parsons A., Krishna G., Martinho M., et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007, 27(6):825-834.
116. Conte L., Ramis J., Mis R., et al. Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole. Arzneimittelforschung 1992, 42(6):854-858.
117. Bensignor E., Grandemange E. Comparison of an antifungal agent with a mixture of antifungal, antibiotic and corticosteroid agents for the treatment of Malassezia species otitis in dogs. Vet Rec 2006, 158(6):193-195.
118. Benitah N. Canine nasal aspergillosis. Clin Tech Small Anim Pract 2006, 21(2):82-88.
119. Peeters D., Clercx C. Update on canine sinonasal aspergillosis. Vet Clin North Am Small Anim Pract 2007, 37(5):901-916. vi.
120. Furrow E., Groman R.P. Intranasal infusion of clotrimazole for the treatment of nasal aspergillosis in two cats. J Am Vet Med Assoc 2009, 235(10):1188-1193.
121. Tomsa K., Glaus T.M., Zimmer C., et al. Fungal rhinitis and sinusitis in three cats. J Am Vet Med Assoc 2003, 222(10):1380-1384. 1365.
122. Mathews K.G., Davidson A.P., Koblik P.D., et al. Comparison of topical administration of clotrimazole through surgically placed versus nonsurgically placed catheters for treatment of nasal aspergillosis in dogs: 60 cases (1990-1996). J Am Vet Med Assoc 1998, 213(4):501-506.
123. Schuller S., Clercx C. Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole. J Am Anim Hosp Assoc 2007, 43(1):33-38.
124. Zonderland J.L., Stork C.K., Saunders J.H., et al. Intranasal infusion of enilconazole for treatment of sinonasal aspergillosis in dogs. J Am Vet Med Assoc 2002, 221(10):1421-1425.
125. Caulkett N., Lew L., Fries C. Upper-airway obstruction and prolonged recovery from anesthesia following intranasal clotrimazole administration. J Am Anim Hosp Assoc 1997, 33(3):264-267.
126. Sucher A.J., Chahine E.B., Balcer H.E. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009, 43(10):1647-1657.
127. Turner M.S., Drew R.H., Perfect J.R. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 2006, 11(2):231-250.
128. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007, 27(3):369-388.
129. Lamaris G.A., Lewis R.E., Chamilos G., et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008, 198(2):186-192.
130. Tawara S., Ikeda F., Maki K., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrobial Agents Chemother 2000, 44(1):57-62.
131. Nakai T., Uno J., Ikeda F., et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrobial Agents Chemother 2003, 47(4):1376-1381.
132. Chandrasekar P.H., Sobel J.D. Micafungin: a new echinocandin. Clin Infect Dis 2006, 42(8):1171-1178.
133. Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrobial Agents Chemother 2004, 48(6):2021-2024.
134. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39(10):1407-1416.
135. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113(4):294-299.
136. Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opin Pharmacother 2009, 10(16):2723-2733.
137. Shear N.H., Villars V.V., Marsolais C. Terbinafine: an oral and topical antifungal agent. Clin Dermatol 1991, 9(4):487-495.
138. Ryder N.S. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992, 126(Suppl 39):2-7.
139. Faergemann J., Zehender H., Denouel J., et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993, 73(4):305-309.
140. McClellan K.J., Wiseman L.R., Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 1999, 58(1):179-202.
141. Gupta A.K., Cooper E.A. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008, 166(5-6):353-367.
142. Hofbauer B., Leitner I., Ryder N.S. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. Med Mycol 2002, 40(2):179-183.
143. Guillot J., Bensignor E., Jankowski F., et al. Comparative efficacies of oral ketoconazole and terbinafine for reducing Malassezia population sizes on the skin of Basset Hounds. Vet Dermatol 2003, 14(3):153-157.
144. Rosales M.S., Marsella R., Kunkle G., et al. Comparison of the clinical efficacy of oral terbinafine and ketoconazole combined with cephalexin in the treatment of Malassezia dermatitis in dogs-a pilot study. Vet Dermatol 2005, 16(3):171-176.